These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7922979)

  • 21. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer.
    Stephens RW; Brünner N; Jänicke F; Schmitt M
    Breast Cancer Res Treat; 1998; 52(1-3):99-111. PubMed ID: 10066075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer.
    Foekens JA; Buessecker F; Peters HA; Krainick U; van Putten WL; Look MP; Klijn JG; Kramer MD
    Cancer Res; 1995 Apr; 55(7):1423-7. PubMed ID: 7882345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer.
    Schrohl AS; Holten-Andersen MN; Peters HA; Look MP; Meijer-van Gelder ME; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 2004 Apr; 10(7):2289-98. PubMed ID: 15073104
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasminogen activator inhibitor type 2 in breast cancer.
    Duggan C; Kennedy S; Kramer MD; Barnes C; Elvin P; McDermott E; O'Higgins N; Duffy MJ
    Br J Cancer; 1997; 76(5):622-7. PubMed ID: 9303361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time-varying prognostic impact of tumour biological factors urokinase (uPA), PAI-1 and steroid hormone receptor status in primary breast cancer.
    Schmitt M; Thomssen C; Ulm K; Seiderer A; Harbeck N; Höfler H; Jänicke F; Graeff H
    Br J Cancer; 1997; 76(3):306-11. PubMed ID: 9252196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
    Pedersen AN; Christensen IJ; Stephens RW; Briand P; Mouridsen HT; Danø K; Brünner N
    Cancer Res; 2000 Dec; 60(24):6927-34. PubMed ID: 11156392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts.
    Sweep CG; Geurts-Moespot J; Grebenschikov N; de Witte JH; Heuvel JJ; Schmitt M; Duffy MJ; Jänicke F; Kramer MD; Foekens JA; Brünner N; Brugal G; Pedersen AN; Benraad TJ
    Br J Cancer; 1998 Dec; 78(11):1434-41. PubMed ID: 9836475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
    Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.